BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 20940403)

  • 21. MicroRNA-196a overexpression promotes cell proliferation and inhibits cell apoptosis through PTEN/Akt/FOXO1 pathway.
    Shang Y; Wang LQ; Guo QY; Shi TL
    Int J Clin Exp Pathol; 2015; 8(3):2461-72. PubMed ID: 26045752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells.
    Fu X; Tian J; Zhang L; Chen Y; Hao Q
    FEBS Lett; 2012 May; 586(9):1279-86. PubMed ID: 22465665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXO3a mediates the cytotoxic effects of cisplatin in lung cancer cells.
    Liu H; Yin J; Wang C; Gu Y; Deng M; He Z
    Anticancer Drugs; 2014 Sep; 25(8):898-907. PubMed ID: 24814195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
    Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisplatin Induces Overactivation of the Dormant Primordial Follicle through PTEN/AKT/FOXO3a Pathway which Leads to Loss of Ovarian Reserve in Mice.
    Chang EM; Lim E; Yoon S; Jeong K; Bae S; Lee DR; Yoon TK; Choi Y; Lee WS
    PLoS One; 2015; 10(12):e0144245. PubMed ID: 26656301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin.
    Arimoto-Ishida E; Ohmichi M; Mabuchi S; Takahashi T; Ohshima C; Hayakawa J; Kimura A; Takahashi K; Nishio Y; Sakata M; Kurachi H; Tasaka K; Murata Y
    Endocrinology; 2004 Apr; 145(4):2014-22. PubMed ID: 14701673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.
    Mitsuuchi Y; Johnson SW; Selvakumaran M; Williams SJ; Hamilton TC; Testa JR
    Cancer Res; 2000 Oct; 60(19):5390-4. PubMed ID: 11034077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rab25 is responsible for phosphoinositide 3-kinase/AKT‑mediated cisplatin resistance in human epithelial ovarian cancer cells.
    Fan Y; Wang L; Han X; Liu X; Ma H
    Mol Med Rep; 2015 Mar; 11(3):2173-8. PubMed ID: 25405658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The effect and mechanism of vinorelbine on cisplatin resistance of human lung cancer cell line A549/DDP].
    Qi C; Gao S; Li H; Gao W
    Zhongguo Fei Ai Za Zhi; 2014 Feb; 17(2):148-54. PubMed ID: 24581167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway.
    Chen Q; Qin R; Fang Y; Li H
    Cell Physiol Biochem; 2015; 36(3):956-65. PubMed ID: 26087719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel].
    Yan XJ; Liang LZ; Zeng ZY; Shi Z; Fu LW
    Ai Zheng; 2006 Apr; 25(4):398-403. PubMed ID: 16613669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells.
    Yuan Z; Wang F; Zhao Z; Zhao X; Qiu J; Nie C; Wei Y
    PLoS One; 2011; 6(5):e20586. PubMed ID: 21655183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells.
    Zhu N; Gu L; Li F; Zhou M
    Mol Cancer Ther; 2008 May; 7(5):1101-9. PubMed ID: 18483299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
    Li T; Cai J; Ding H; Xu L; Yang Q; Wang Z
    Cancer Biol Ther; 2014 Mar; 15(3):271-8. PubMed ID: 24335192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
    Dziegielewska B; Casarez EV; Yang WZ; Gray LS; Dziegielewski J; Slack-Davis JK
    Mol Cancer Ther; 2016 Mar; 15(3):460-70. PubMed ID: 26832797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hexabromocyclododecane and polychlorinated biphenyls increase resistance of hepatocellular carcinoma cells to cisplatin through the phosphatidylinositol 3-kinase/protein kinase B pathway.
    An J; Wang X; Guo P; Zhong Y; Zhang X; Yu Z
    Toxicol Lett; 2014 Aug; 229(1):265-72. PubMed ID: 24960055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer.
    Qazi AK; Hussain A; Khan S; Aga MA; Behl A; Ali S; Singh SK; Taneja SC; Shah BA; Saxena AK; Mondhe DM; Hamid A
    Cancer Lett; 2015 Apr; 359(1):47-56. PubMed ID: 25554016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.